The clinical efficacy of PD-1/PD-L1 inhibition has been observed for various malignancies, such as melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). This evidence concerns the gene PDCD1 and renal cell carcinoma.